(MedPage Today) — WASHINGTON — Daily treatment with the investigational oral agent HU6 reduced liver fat and body weight without muscle loss in patients with metabolic dysfunction-associated steatohepatitis (MASH), according to the phase IIa…
Source link : https://www.medpagetoday.com/meetingcoverage/aasld/118468
Author :
Publish date : 2025-11-12 15:42:00
Copyright for syndicated content belongs to the linked Source.
